Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD - Online CME

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

FDA Fast Track designation for novel selective cardiac myosin activator in HF

News - May 26, 2020

Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.

SBP of 120-129 mmHg associated with lowest risk of outcomes in HFpEF

Literature - May 14, 2020 - Selvaraj S et al., - J Am Coll Cardiol. 2020

This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.

SGLT2i approved by FDA for treatment of HFrEF

News - May 11, 2020

The FDA approved dapagliflozin for treatment of heart failure patients with reduced ejection fraction to reduce CV death and hospitalization for HF.

AF associated with increased CV and total mortality in East Asian HFpEF patients

Literature - May 6, 2020 - Son MK, et al. - Heart. 2020

In a study of acute HF patients in a Korean registry, AF was more prevalent with increasing EF, and associated with increased CV and total mortality in HFpEF patients and increased risk of stroke in HFrEF and HFpEF patients.

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

Reviewing HFpEF: Lessons and implications from PARAGON-HF

EBAC-accredited E-Learning

Online-CME - This course consists of 3 lectures.
This course consists of 3 lectures.

This series aims to provide cardiologists and other health care professionals involved in the management of heart failure patients a well-balanced expert view on findings of the PARAGON-HF and other trials, with implications for the whole ejection fraction range. Member registration (free) is needed to enroll in this course.

Consistent treatment benefit of SGLT2i in HFrEF patients, regardless of background therapy

News - Apr. 16, 2020

ACC 2020 This post-hoc analysis of the DAPA-HF trial showed a consistent treatment benefit of dapagliflozin in HFrEF patients compared with placebo, regardless of background therapy.

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD
Jonathan Cunningham discusses three findings from subanalyses of the PARAGON-HF trial in HFpEF patients.

ACC 2020 Jonathan Cunningham shares three major findings from a subanalysis of the PARAGON-HF trial in HFpEF patients.

ARNI treatment reduces NT-proBNP levels in HFpEF patients

News - Apr. 8, 2020

ACC 2020 A subanalysis of the PARAGON-HF trial demonstrated that treatment with the ARNI sacubitril/valsartan reduced NT-proBNP levels with 19% compared to valsartan alone in HFpEF.

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020
The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.